U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H25ClFN5O3.2ClH
Molecular Weight 558.86
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CANERTINIB DIHYDROCHLORIDE

SMILES

Cl.Cl.FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1

InChI

InChIKey=JZZFDCXSFTVOJY-UHFFFAOYSA-N
InChI=1S/C24H25ClFN5O3.2ClH/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16;;/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29);2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C24H25ClFN5O3
Molecular Weight 485.938
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Canertinib or CI-1033 (N-[4-[N-(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]acrylamide) is a pan-erbB tyrosine kinase inhibitor. It selectively inhibits erbB1 (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concentrations. Canertinib was under development by Pfizer Inc as a potential treatment for cancer.

Approval Year

Doses

Doses

DosePopulationAdverse events​
337.5 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 337.5 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 337.5 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
DLT: hypersensitivity reaction, diarrhea...
Dose limiting toxicities:
hypersensitivity reaction (grade 3, 2 patients)
diarrhea (grade 3, 2 patients)
Sources:
500 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 500 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 500 mg, 3 times / week
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
DLT: Myalgia, syncope...
Dose limiting toxicities:
Myalgia (grade 3, 2 patients)
syncope (2 patients)
Sources:
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
DLT: emesis, rash...
Other AEs: Diarrhea...
Dose limiting toxicities:
emesis (grade 2, 1 pt)
rash (grade 2, 1 pt)
mouth ulcer (grade 2, 1 pt)
emesis (grade 3, 1 pt)
Other AEs:
Diarrhea (grade 1-2, 2 patients)
Sources:
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Other AEs: Dyspnea, Infection...
Other AEs:
Dyspnea (1 pt)
Infection (3 patients)
Thrombocytopenia (1 pt)
Cutaneous toxicities (7 patients)
Pain (2 patients)
Asthenia (2 patients)
Vasodilation (2 patients)
Stomatitis (2 patients)
Myalgia (2 patients)
Vomiting (2 patients)
Nausea (2 patients)
Sources:
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
DLT: thrombocytopenia...
Other AEs: Emesis, rash...
Dose limiting toxicities:
thrombocytopenia (grade 4, 1 pt)
Other AEs:
Emesis (grade 3, 1 pt)
rash (grade 1-2, 7 patients)
Hypersensitivity (grade 1-2, 3 patients)
Mucositis (grade 1-2, 6 patients)
Nausea (grade 1-2, 5 patients)
iarrhea (grade 1-2, 3 patients)
Sources:
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Disc. AE: Diarrhea...
Other AEs: Abdominal pain, Asthenia...
AEs leading to
discontinuation/dose reduction:
Diarrhea (13%)
Other AEs:
Abdominal pain (13%)
Asthenia (13%)
Sources:
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
Disc. AE: diarrhea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
diarrhea (10%)
Abdominal pain (10%)
Asthenia (10%)
Sources:
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
DLT: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 3, 1 pt)
Sources:
560 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 560 mg, 1 times / day
Route: oral
Route: multiple
Dose: 560 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
DLT: Hypersensitivity...
Dose limiting toxicities:
Hypersensitivity (grade 3, 1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
diarrhea grade 3, 2 patients
DLT
337.5 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 337.5 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 337.5 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
hypersensitivity reaction grade 3, 2 patients
DLT
337.5 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 337.5 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 337.5 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
syncope 2 patients
DLT
500 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 500 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 500 mg, 3 times / week
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
Myalgia grade 3, 2 patients
DLT
500 mg 3 times / week multiple, intravenous (total daily dose)
Highest studied dose
Dose: 500 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 500 mg, 3 times / week
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
Diarrhea grade 1-2, 2 patients
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
emesis grade 2, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
mouth ulcer grade 2, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
rash grade 2, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
emesis grade 3, 1 pt
DLT
750 mg 1 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 750 mg, 1 times / day
Route: oral
Route: multiple
Dose: 750 mg, 1 times / day
Sources:
unhealthy
n = 3
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
Dyspnea 1 pt
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Thrombocytopenia 1 pt
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Asthenia 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Myalgia 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Nausea 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Pain 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Stomatitis 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Vasodilation 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Vomiting 2 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Infection 3 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Cutaneous toxicities 7 patients
225 mg 3 times / week multiple, intravenous (total daily dose)
MTD
Dose: 225 mg, 3 times / week
Route: intravenous
Route: multiple
Dose: 225 mg, 3 times / week
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: advanced nonhematologic malignancies
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Hypersensitivity grade 1-2, 3 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
iarrhea grade 1-2, 3 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Nausea grade 1-2, 5 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Mucositis grade 1-2, 6 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
rash grade 1-2, 7 patients
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Emesis grade 3, 1 pt
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
thrombocytopenia grade 4, 1 pt
DLT
650 mg 1 times / day multiple, oral (total daily dose)
MTD
Dose: 650 mg, 1 times / day
Route: oral
Route: multiple
Dose: 650 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Abdominal pain 13%
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Asthenia 13%
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Diarrhea 13%
Disc. AE
200 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 52
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 52
Sources:
Abdominal pain 10%
Disc. AE
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
Asthenia 10%
Disc. AE
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
diarrhea 10%
Disc. AE
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 53
Health Status: unhealthy
Condition: ovarian cancer
Sex: F
Food Status: UNKNOWN
Population Size: 53
Sources:
Thrombocytopenia grade 3, 1 pt
DLT
50 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: Refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
Hypersensitivity grade 3, 1 pt
DLT
560 mg 1 times / day multiple, oral (total daily dose)
Studied dose
Dose: 560 mg, 1 times / day
Route: oral
Route: multiple
Dose: 560 mg, 1 times / day
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: refractory cancer
Sex: M+F
Food Status: UNKNOWN
Population Size: 8
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
2000 Apr 6
Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.
2000 Dec 1
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.
2002 Jun
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
2006 Aug 1
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
2007 Mar
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Patents

Patents

Sample Use Guides

According to the phase I pharmacokinetic study canertinib (CI-1033) was safely given i.v. up to 225 mg/dose on a thrice-weekly schedule, with evidence of antitumor activity. At equivalent doses, the bioavailability of i.v. CI-1033 is thrice that of the oral formulation.
Route of Administration: Other
The effect of canertinib (CI-1033) on esophageal cancer cell proliferation was investigated in the TT, TE2, TE6 and TE10 cell lines. After one day of treatment with CI-1033 (0.1-5.0 nM) significant inhibition of cell growth was observed in all cell lines at all concentrations of CI-1033 examined. The dose of CI-1033 required to inhibit the cell growth was as low as 0.1 nM. The inhibitory effect of CI-1033 on cancer cell growth was dose- and time-dependent.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:34:51 UTC 2023
Edited
by admin
on Wed Jul 05 23:34:51 UTC 2023
Record UNII
ICJ93X8X90
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANERTINIB DIHYDROCHLORIDE
MI   USAN   WHO-DD  
USAN  
Official Name English
N-[4-(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-yl)propoxy]quinazolin-6-yl]prop-2-enamide dihydrochloride
Common Name English
CANERTINIB DIHYDROCHLORIDE [USAN]
Common Name English
CANERTINIB DIHYDROCHLORIDE [MI]
Common Name English
PD-0183805-002B
Code English
Canertinib dihydrochloride [WHO-DD]
Common Name English
N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-(3-(4-MORPHOLINYL)PROPOXY)-6-QUINAZOLINYL)-2-PROPENAMIDE DIHYDROCHLORIDE
Systematic Name English
CI-1033
Code English
2-PROPENAMIDE, N-(4-((3-CHLORO-4-FLUOROPHENYL) AMINO)-7-(3-(4-MORPHOLINYL)PROPOXY)-6-QUINAZOLINYL)-, DIHYDROCHLORIDE
Common Name English
PD-0183805
Code English
CANERTINIB HYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
NCI_THESAURUS C2167
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C1880
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
CAS
289499-45-2
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
CHEBI
61399
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
PUBCHEM
156413
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
ChEMBL
CHEMBL31965
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
FDA UNII
ICJ93X8X90
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID80183143
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
EVMPD
SUB25455
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
DRUG BANK
DBSALT002500
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
SMS_ID
100000089476
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
MESH
C420268
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
USAN
NN-49
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY
MERCK INDEX
M3017
Created by admin on Wed Jul 05 23:34:51 UTC 2023 , Edited by admin on Wed Jul 05 23:34:51 UTC 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY